ClinicalTrials.gg
CompletedNCT01719575DA-9701Updated Aug 15, 2013

Clinical Trial of Motilitone on Gastric Motor Function in Healthy Volunteers

A Phase 4 interventional study of Motilitone and Placebo in Healthy Female and Male, sponsored by Dong-A Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-15.

Sponsored by Dong-A Pharmaceutical Co., Ltd. · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the effects of Motilitone and placebo on gastric volumes, gastric emptying, small bowel transit and colon transit in female and male healthy volunteers.

02

Conditions studied

  • Healthy Female and Male
03

In context

Lead sponsor

Dong-A Pharmaceutical Co., Ltd. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • no gastrointestinal symptoms
  • no organic lesion such as gastrointestinal , erosive esophagitis, reflux esophagitis, erosive gastroduodenitis, gastric or duodenal ulceration after having normal upper abdominal endoscopy
  • written

Exclusion criteria

Exclusion Criteria:

  • pregnant, breast-feeding female,those of childbearing age who were not using an approved method of
  • history of abdominal surgery that may influence gastrointestinal motility
  • gastrointestinal hemorrhage, mechanical ileus, enterobrosis
  • irritable bowel syndrome, inflammatory bowel disease
  • severe disturbance of liver, kidney, heart,lung,blood and endocrine
  • psychoneurosis, alcoholism, drug dependence
  • medications that may alter evaluation of Motilitone including antibiotics,, NSAID within 1 month, prokinetics, H2 blocker, PPI, anticolines, erythromycin, antidepressive agents withing 2weeks
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Other
    Motilitone

    take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week

    Drug: Motilitone

  • Other
    Placebo

    take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. gastric fuction of Motilitone

    gastric emptying time on day 4 by scintigraphic imaging

    Time frame: 3 weeks

  2. gastric function of Motilitone

    fasting and postprandial gastric volume on day 7 by single photon emission computed tomography

    Time frame: 3 weeks

Secondary outcomes

  1. adverse events of Motilitone

    Time frame: 3 weeks

  2. small bowel function of Motilitone

    small bowel transit time on day 4 by scintigraphic transit measurement

    Time frame: 3 weeks

  3. Colon function of Motilitone

    colon transit time on day 4 and 7 by KUB

    Time frame: 3 weeks

07

Study locations

1 site
  • the Catholic university of korea college of Medicine, Seoul St.Mary's hospital
    Banpo-dong, Seocho-gu, Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012 and a primary completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2012
First posted
Nov 1, 2012
Start
Mar 2012
Primary completionActual
Nov 2012
Last update
Aug 15, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01719575
Responsible party
Sponsor
First posted
Nov 1, 2012
Start date
Mar 2012
Primary completion
Nov 2012
Last update
Aug 15, 2013

Study contacts

Myung-Gyu Choi, Ph.D.
principal investigator · Seul St.Mary's hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DA-9701

Start the discussion